Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis
| العنوان: | Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis |
|---|---|
| المؤلفون: | Graciela Molinero, Walter Masson, Augusto Lavalle-Cobo, Martín Lobo, Gerardo Masson |
| المصدر: | High Blood Pressure & Cardiovascular Prevention. 28:605-612 |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, education.field_of_study, Cardiotonic Agents, business.industry, Population, Type 2 diabetes, medicine.disease, Glucagon-Like Peptide-1 Receptor, Metformin, Confidence interval, Clinical trial, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Clinical endpoint, Humans, Cardiology and Cardiovascular Medicine, education, business, Mace, medicine.drug |
| الوصف: | Sodium Glucose Co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs) were associated with a reduction in cardiovascular disease events in cardiovascular outcomes trials (CVOTs) in type 2 diabetes. Most of the patients included in these trials received metformin as background therapy. To evaluate the effect of glucagon-like peptide 1 receptor agonists on major cardiovascular events (MACE) and mortality in metformin-naive patients with type 2 diabetes. A systematic review and meta-analysis of randomized controlled clinical trials of GLP-1RAs on type 2 diabetes population was performed, after searching the PubMed/MEDLINE, Embase, Scielo, Google Scholar and Cochrane Controlled Trials databases. The primary endpoint was MACE. The secondary endpoints were cardiovascular death and all-cause mortality. A meta-analysis of time-to-event outcomes was performed. This meta-analysis was registered in PROSPERO (CRD42021260040) Seven trials, including 11510 patients, were identified and considered eligible for the analyses. GLP-1RAs were associated with a significant reduction in MACE incidence (HR: 0.86, 95% confidence interval: 0.79–0.94; I2: 0%). The secondary endpoints analysis showed a non-significant reduction in all-cause mortality (HR: 0.86, 95% confidence interval: 0.73–1.00 I2: 0%) and cardiovascular mortality (HR: 0.81, 95% confidence interval: 0.63–1.05; I2: 0%). In this meta-analysis, GLP-1RAs reduced the incidence of MACE in patients with type 2 diabetes without metformin at baseline, without significant reduction in all-cause mortality and cardiovascular mortality. These results support the fact that when a GLP-1RAs is administered, the benefit on cardiovascular outcomes is independent of the use of metformin. |
| تدمد: | 1179-1985 1120-9879 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd73b7724e74ab9b2f4cb0eab5a759c6Test https://doi.org/10.1007/s40292-021-00479-1Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....dd73b7724e74ab9b2f4cb0eab5a759c6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 11791985 11209879 |
|---|